Orphan designation: Mavorixafor, Treatment of WHIM syndrome, 25/07/2019, Positive

On 25 July 2019, orphan designation EU/3/19/2183 was granted by the European Commission to Voisin Consulting S.A.R.L., France, for mavorixafor for the treatment of WHIM syndrome.

In October 2021, Voisin Consulting S.A.R.L. changed name to Voisin Consulting Life Sciences.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

You just read:

Orphan designation: Mavorixafor, Treatment of WHIM syndrome, 25/07/2019, Positive

Distribution channels: Healthcare & Pharmaceuticals Industry

EIN Presswire's priority is author transparency. We do our best to weed out false and misleading content. The content above is the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above.